Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Preconception psychotropic review

Psychiatry · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Unexpected pregnancy or acute deterioration

A positive pregnancy test while taking valproate, lithium or another medicine needing specialist review requires prompt coordinated advice, while suicidality, mania, psychosis, severe agitation or inability to maintain safety requires same-day emergency mental-health assessment.

Action: Confirm the medicine, dose, adherence, last menstrual period and immediate mental state; do not advise abrupt self-discontinuation; contact the relevant psychiatric and obstetric or medicines-in-pregnancy specialists urgently, and use emergency services when the person, fetus, baby or another person may be in immediate danger.

Synopsis

Plan conception without destabilising mental health by reviewing reproductive intentions, relapse history, psychotropic exposure, physical health, contraception and the support needed before, during and after pregnancy.

  • Ask about pregnancy intentions at routine reviews; do not wait until a prescription is due or pregnancy has occurred.
  • Map previous episodes, admissions, suicide risk, postpartum illness, treatment response and the consequences of past withdrawal before recommending any change.
  • Refer a person with current or past severe mental illness who is planning pregnancy for specialist perinatal preconception counselling.
  • Compare four exposures explicitly: untreated or relapsing illness, continuing treatment, switching treatment, and stopping treatment.
  • Prefer an effective medicine with the lowest appropriate risk profile, the lowest effective rather than subtherapeutic dose, and monotherapy where clinically possible.
  • Never frame a positive pregnancy test as a reason to stop psychotropics suddenly; establish an urgent, named review route.
  • Valproate must not be prescribed to a woman or girl able to have children unless Pregnancy Prevention Programme conditions are met; initiation under age 55 also has current two-specialist restrictions.
  • If lithium is continued in pregnancy, plan level monitoring, hydration, hospital birth, labour management and postnatal relapse prevention before conception.
  • Record contraception, folate advice from the relevant obstetric or epilepsy pathway, smoking, alcohol, non-prescribed drugs, BMI, blood pressure and medicine-specific physical monitoring.
  • Give the person a written plan naming who will prescribe, who to contact after a positive test, early relapse signs and the intended first postnatal review.

Key red flags

Current suicidal intent, psychosis, mania, severe self-neglect or rapidly falling function overrides a routine preconception appointment and needs urgent specialist assessment.

Pregnancy while taking valproate requires urgent specialist contact because exposure carries major fetal risks, but abrupt unsupervised cessation can precipitate relapse or seizures.

A history of postpartum psychosis, bipolar disorder or another severe mental illness predicts a need for specialist perinatal planning before conception and enhanced surveillance after birth.

Lithium toxicity symptoms, dehydration, vomiting, interacting medicines or renal deterioration need an urgent level and clinical review rather than a scheduled reproductive discussion.

Coercive control, reproductive coercion, domestic abuse or inability to use agreed contraception safely requires private enquiry and safeguarding support.

Investigation priorities

01
Pregnancy intention and contraception reviewFirst step

Establish current pregnancy possibility, desired timing and whether contraception is acceptable, effective and safely controlled by the person.

Management branches

Shared formulationDefine illness and reproductive priorities

A person taking or likely to need psychotropic treatment may conceive in the foreseeable future.

  1. Clarify reproductive intention, contraception, fertility concerns, preferred terminology and who may be involved in decisions.
  2. Build the relapse and response history, including any postpartum episode and the effect of previous stopping or switching.
  3. Present continuing, changing and stopping options with both illness-related and medicine-related consequences, then document the person's informed priorities.

Key medicines

Valproate reproductive safety actionDo not initiate valproate in a new patient younger than 55 unless two specialists independently document the MHRA exception; do not prescribe it to a woman or girl able to have children unless Pregnancy Prevention Programme conditions are fulfilled. Any withdrawal is specialist-led and gradual rather than abrupt.Exposure in pregnancy is associated with physical birth defects in about 11% of babies and neurodevelopmental disorders in up to 30–40% of children. Use the current annual risk materials. Counsel men about the precautionary three-month contraception and sperm-donation interval; the paternal causal association remains unconfirmed.
Lithium preconception strategyUse an individualised specialist regimen titrated to the person's established 12-hour plasma target; there is no universal reproductive dose. If a well pregnant person elects to stop, NICE describes gradual withdrawal over 4 weeks, while high relapse risk may justify supervised continuation or another specialist option.Discuss uncertain-size fetal cardiac-malformation risk with first-trimester exposure, high transfer into breast milk and infant toxicity concern, renal and thyroid status, interactions, dehydration and the marked postnatal relapse risk. Continuing treatment requires a detailed pregnancy, labour and postnatal monitoring plan.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE CG192 recommendationsPreconception referral, shared decisions, medicine principles and lithium planning.
  • MHRA valproate reproductive materialsCurrent initiation restrictions, Pregnancy Prevention Programme and June 2025 materials.
  • MHRA paternal valproate advicePrecautionary contraception, sperm donation and counselling interval for men.
  • RCPsych perinatal mental health servicesSpecialist preconception counselling and coordinated perinatal service roles.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom